You are viewing an inactive listing

This listing is not currently available. You can either be notified when it becomes available or browse nearby active listings below.

Click here to view additional nearby listings or search by keyword.

Dilworth, Minnesota 56529

  • Healthy


The objectives of this study are to evaluate the adhesion performance and pharmacokinetics of ZTlido (lidocaine topical system) 1.8% during swimming, showering, and under normal conditions.

Study summary:

In this Phase 1, open-label, three-period crossover study, 24 healthy, adult male and female subjects are randomized to 1 of 3 treatment sequences. During each treatment period, subjects have one lidocaine topical system applied to their back for 12 hours with a 4-day washout between treatments. In each treatment period, the subject will either swim (Treatment A), shower (Treatment B), or refrain from these activities (Treatment C) while wearing the topical system. Blood samples for lidocaine PK will be collected pre-dose until 24 hours. Adhesion will be monitored throughout the wear time and skin irritation will be assessed the topical system is removed.


Key Inclusion Criteria: - Must be healthy based on medical history, laboratory work, and physical exam - Body mass index ranging between 18.0-30.0 kg/m2, inclusive - Capable of unaided swimming - If childbearing potential, use of acceptable form of birth control - In case of females of childbearing potential, have a negative serum pregnancy Key Exclusion Criteria: - Allergy or known hypersensitivity to lidocaine, amide-type local anesthetics or any component of the product formulation - Any major medical illness 3 months prior or any significant history or ongoing chronic medical illness affecting the major body systems, including the skin - Subjects with conditions that might affect application of the product or its adhesive properties (including psoriasis, eczema, atopic dermatitis, damaged or irritated epidermal layer, and excessive hair or oil on the skin) - Use of antiarrhymthic drugs (such as tocainide and mexiletine) and local anesthetics within 14 days prior to product application. - History of addiction, abuse, or misuse of any drug - Use of nicotine-containing products within 30 days



Primary Contact:

Principal Investigator
Peter Boldingh, PharmD
AXIS Clinicals

Backup Contact:


Location Contact:

Dilworth, Minnesota 56529
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 19, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.